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Abstract 
Background: Prepulse inhibition (PPI) of the acoustic startle response (ASR) is an operational 
measure of sensorimotor gating and a promising endophenotype of schizophrenia. We have recently 
shown that the linked serotonin-2A receptor (5-HT2AR) A-1438G and T102C polymorphisms 
modulate PPI in schizophrenia patients. Moreover, it was shown that genetic variation in the catechol-
O-methyltransferase (COMT) and the neuregulin-1 (NRG-1) proteins influences PPI in schizophrenia 
patients and healthy volunteers. Therefore, we aimed to replicate these results and investigated the 
impact of the related polymorphisms on PPI in healthy human volunteers. 
Methods: We analyzed the 5-HT2AR A-1438G/T102C (rs6311/rs6313), the COMT Val158Met 
(rs4680), and the NRG-1 Arg38Gln (rs3924999) polymorphisms, assessed startle reactivity, 
habituation, and PPI of ASR in 107 healthy Caucasian volunteers.  
Results: Subjects homozygous for the 5-HT2AR T102C-T/A-1438G-A allele showed increased PPI 
levels. In particular, male subjects with the COMT Met158Met-genotype showed also elevated PPI. 
The NRG-1 Arg38Gln genotype did not have a significant impact on PPI. Startle reactivity was not 
affected by any of the investigated polymorphisms. 
Conclusions: We confirmed in an independent sample of healthy volunteers that PPI is influenced by 
genetic variation in the 5-HT2AR gene. The influence of the COMT Val158Met genotype on PPI 
appears gender-specific. These results underscore the significance of the serotonin and dopamine 
systems in the modulation of sensorimotor gating.  
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Introduction 
Prepulse inhibition (PPI) of the acoustic startle response (ASR) is widely used as an operational 
measure of sensorimotor gating (1). PPI refers to the reduction of ASR magnitude when a distinctive 
non-startling stimulus is presented 30 to 500 msec before a startling stimulus (2). It was proposed that 
the mechanism underlying PPI regulates sensory input by filtering out irrelevant or distracting stimuli 
to prevent sensory information overflow (1). 
 
PPI was suggested as a promising endophenotype of schizophrenia for several reasons (3): I.) 
Schizophrenia patients consistently show PPI deficits (4), II.) Unaffected first-degree relatives of 
schizophrenia patients also exhibit decreased PPI levels (5,6), III.) The PPI deficit seems to be a trait 
marker of schizophrenia as it is already present in the prodromal phase of schizophrenia (7), IV.) 
Inbred rodent studies and human twin studies suggested that PPI is heritable (8-10) and V.) PPI is 
measurable in a wide range of species in which PPI deficits could be artificially induced by 
environmental or pharmacological manipulations. This offers the possibility to study the 
neurobiological basis of PPI in translational investigations (1). 
 
Recently, several single nucleotide polymorphisms (SNPs) have been reported to strongly affect PPI 
thereby illuminating both the molecular mechanisms and genetic influences on sensorimotor gating. 
Initially, Hong et al. (11) found that the neuregulin-1 (NRG-1) Arg38Gln SNP modulates PPI in 
healthy volunteers and schizophrenia patients. Roussos et al. (12) followed with their finding that the 
catechol-O-methyltransferase (COMT) Val158Met SNP affects PPI in healthy male volunteers, a 
discovery which we recently replicated in a mixed-sex sample of schizophrenia patients (13). 
Additionally, we showed that the serotonin-2A receptor (5-HT2AR) A-1438G and T102C SNPs (which 
are in complete linkage disequilibrium) are associated with PPI in schizophrenia patients (14). Most 
recently, it has been demonstrated that PPI also depends on the dopamine-D3 receptor Ser9Gly SNP 
(15). All of these SNPs have at some stage been suggested as susceptibility polymorphisms for 
schizophrenia (e.g., 16,17) but current meta-analyses do not support their role in aetiology of the 
disease itself, with the exception of the 5-HT2AR A-1438G polymorphism which may have a small 
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effect on the risk for schizophrenia (SchizophreniaGene: www.schizophreniaforum.org/res/sczgene) 
(18). 
 
Replication is essential for establishing the credibility of genotype-phenotype associations (19). 
Therefore, we investigated the impact of four SNPs, which were previously linked to sensorimotor 
gating and schizophrenia, on PPI in a new and independent sample of healthy human volunteers: The 
linked 5-HT2AR T102C/A-1438G, the COMT Val158Met, and the NRG-1 Arg38Gln polymorphisms. 
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Methods and Materials  
Participants 
One hundred and seven Caucasian healthy volunteers (49.5% women; 24.3% smoker; mean age 26.2 
±5.8 [SD] years, range: 18 to 43) were recruited through local advertisements in South London (UK). 
Participants were screened for the exclusion criteria of DSM-IV Axis I disorders using the Structured 
Clinical Interview for DSM-IV Disorders (SCID-I). Additional exclusion criteria were a history of 
head injuries, any known neurological abnormalities or systemic illness with known neurological 
complication, a first-degree relative with psychosis or obsessive-compulsive disorder, and a history of 
substance abuse or dependence. Ethical approval of the local ethics committee was obtained and 
participants provided written informed consent. 
 
Genotyping 
DNA was obtained from venal blood or buccal swabs using established procedures (20). 5-HT2AR A-
1438G (rs6311) and T102C (rs6313), COMT Val158Met (rs4680), and NRG-1 Arg38Gln (rs3924999) 
SNP genotyping assays were run as submicroliter PCR-based assays on Array Tape 
(www.douglasscientific.com) at PreventionGenetics (Marshfield, Wisconsin). They used an allele-
specific PCR assay as described by Myakishev et al. (21) (rs6313, rs3924999) or InvaderPlus reactions 
from Third Wave Technologies (Madison, Wisconsin) (rs4680, rs6311). To improve genotyping 
reliability, many samples of similar DNA quality and concentration were genotyped at the same time. 
Genotyping was successful in 93.5% of subjects for 5-HT2AR A-1438G and T102C, in 88.8% for 
COMT Val158Met, and in 95.3% for NRG-1 Arg38Gln SNP. 
 
Startle Response Measurement 
Equipment, set up, PPI testing, and data acquisition and scoring procedures have been described in 
detail previously (22). Each examination began with a 4-min acclimation period of 70-dB background 
noise that was continued throughout the session. Participants received 49 white noise sound pulses at 
an intensity of 115 dB (duration of 40 ms) separated by variable inter-trial intervals between 9 and 23 
s (mean 15 s). In 36 of the trials, the pulse was preceded by a 20-ms 85-dB white noise prepulse with 
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stimulus-onset-asynchronies (SOA) of 30, 60 and 120 ms (12 trials each). The initial trial was a pulse-
alone (PA) trial, which was separated for further analysis. All following trials were presented in a 
pseudorandomized order. The entire test session lasted about 16 min. To ensure that PPI was not 
influenced by smoking withdrawal, smoking ad libitum was permitted before testing (23). Trial 
exclusion and scoring criteria were identical to those used in previous studies (24). Subjects with 
response rejections >50% were excluded from data analysis (n=4).  
 
Statistical analysis 
Startle reactivity was assessed by the mean amplitude of the first block of PA trials and the mean 
amplitude of all PA trials. For the assessment of startle habituation, PA trials were divided each in four 
blocks. The calculation of the mean percent PPI and the habituation measures (percent habituation and 
linear gradient coefficient b) have been described in detail elsewhere (24).  
All demographical data were analyzed by analysis of variance (ANOVA) with exception of frequency 
data. Frequency data were analyzed using χ2 -Tests. Given that gender (25) and smoking (23) could 
affect PPI, these variables were introduced as covariates in all analyses of covariance (ANCOVA) of 
the psychophysiological parameters independent of the statistical significance of the covariates. Based 
on significant main effects or interactions, Tukey-HSD post-hoc comparisons were performed. Given 
that we proposed directional hypotheses regarding the genotype effects on sensorimotor gating, 
statistical comparisons of the PPI data were carried out at a significance level set at p<.05 (2-tailed). 
Considering that we investigated four SNPs, all other confirmatory statistical comparisons were 
carried out at a Bonferroni-corrected significance level of p<.0125 (2-tailed). Within the Pearson 
product-moment correlation analyses, the significance level was set at p<.01 (2-tailed) to avoid 
accumulation of α-error. Effect size calculations between two groups refer to Cohen’s d. When post-
hoc tests of PPI data are reported, Cohen’s d calculations based on pooled SOA-conditions. 
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Results 
5-HT2A T102C and A-1438G receptor polymorphisms 
As expected, the 5-HT2AR T102C and A-1438G polymorphisms were in complete linkage 
disequilibrium [r2=1.0]. Genotype frequencies were distributed in accordance with Hardy-Weinberg 
Equilibrium [HWE; Chi2(1)=1.1; p=.29]. The genotype groups did not differ regarding demographic 
variables, startle reactivity and habituation measures (see Table 1). Moreover, startle latency and 
prepulse latency facilitation was also not affected by 5-HT2AR genotype (data not shown). 
A 3x3 (SOA-condition x genotype) repeated measurement ANCOVA with gender and smoking as 
covariates revealed significant main effects for the factors SOA-condition [F(2,91)=7.7; p<.001; 
η2=.14], gender [F(1,92)=22.2; p<.001; η2=.19], and genotype [F(2,92)=5.0; p<.01; η2=.10] (see 
Figure 1a). Tukey-HSD post-hoc tests revealed that homozygous carriers of the T102C-T/A-1438G-A 
allele did show significantly higher PPI levels compared to homozygous T102C-C/A-1438G-G 
[p<.05; d=0.63] and the heterozygous T102C-TC/A-1438G-AG variants [p<.01; d=0.81]. 
Homozygous T102C-C/A-1438G-G carriers and heterozygous T102C-TC/A-1438G-AG carriers did 
not differ in PPI. The main effect of SOA reflects the well-known nature of PPI to increase with rising 
SOA from 30 msec through 60 msec to 120 msec (26). The effect of gender points to the known fact 
that women have generally lower PPI levels than men [pooled SOA-conditions: F(1,102)=18.3; 
p<.001; η2=.15] (25). 
 
****Insert Table 1*** 
****Insert Figure 1 (a,b,c)*** 
 
COMT Val158Met polymorphism 
The COMT Val158Met genotype frequencies were distributed in accordance to the HWE 
[Chi2(1)=1.9; p=.17]. The three genotype groups did not differ in demographic characteristics, pooled 
PPI scores, startle reactivity and habituation measures (see Table 2).  Startle latency measures were 
also not influenced by COMT-genotype (data not shown). 
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The Met-homozygotes displayed the highest PPI levels but a 3x3 (SOA-condition x genotype) 
repeated measurement ANCOVA with gender and smoking as covariates revealed only significant 
main effects for the factors SOA-condition [F(2,87)=5.5; p<.01; η2=.11] and gender [F(1,88)=13.7; 
p<.001; η2=.13] (see Figure 1b). Given that Roussos et al. (12) have shown their significant effects of 
COMT genotype on PPI only in male subjects, we excluded females from the ANCOVA analysis in a 
further step. Although only 45 males remained, this resulted in a significant main effect of genotype 
[F(2,41)=3.2; p<.05; η2=.13] (see Figure 2). Tukey-HSD post-hoc tests revealed that Met-
homozygotes displayed significantly higher PPI levels compared to heterozygotes [p<.05; d=0.83]. 
Both homozygous groups did not significantly diverge with respect to PPI although the difference did 
show a moderate effect size [d=0.55]. The ValVal group and the ValMet group did not differ. The 
male COMT genotype groups still did not differ in startle reactivity and habituation measures. 
Moreover, if male Met- homozygotes were compared to a merged group of male carriers of the Val-
Allel (ValMet + ValVal) in a 3x2 (SOA-condition x genotype) repeated measurement ANCOVA with 
smoking as a covariate, the Met- homozygotes still showed significantly higher PPI levels that Val-
allele carriers [F(1,42)=6.3, p<.05, η2=.13]. 
 
****Insert Table 2*** 
****Insert Figure 2*** 
 
NRG-1 Arg38Gln polymorphism 
The NRG-1 Arg38Gln genotype frequencies were distributed in accordance with HWE [Chi2(1)=0.04; 
p=.84]. The three genotype groups did not differ regarding demographic characteristics, pooled PPI 
scores, startle reactivity and startle latency measures (see Table 3) but there was a trend for a different 
distribution of gender between the genotype groups. Moreover, there was a strong trend for a genotype 
effect regarding early habituation (see Table 3). The total habituation and the slope of habituation 
revealed a similar but also non-significant pattern of effect as observed for early habituation. 
Although the A-homozygotes showed somewhat higher PPI levels, a 3x3 (SOA-condition x genotype) 
repeated measurement ANCOVA with gender and smoking as covariates revealed significant main 
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effects only for the factors SOA-condition [F(2,93)=9.0; p<.001; η2=.16], and gender [F(1,94)=18.1; 
p<.001; η2=.16] (see Figure 1c).  
 
****Insert Table 3*** 
 
Correlation analysis and genotype interactions 
Age and years of education did not correlate with any of the psychophysiological parameters. A 3x3x3 
(SOA-condition x SNP x genotype) repeated measurement ANCOVA with the three SNPs under 
investigation and gender as a covariate did not show any significant interactions between SNPs. 
Interaction analyses with two SNPs each did also not reveal any interactions. However, these analyses 
should be interpreted with caution because of the limited sample size. 
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Discussion 
The present work aimed to replicate initial findings on the dependency of PPI on polymorphisms of 
the 5-HT2A receptor, the COMT enzyme, and the NRG-1 signal protein in an independent sample of 
healthy human volunteers. First, we confirmed that the 5-HT2AR T102C/A-1438G polymorphisms 
exerts the same impact on sensorimotor gating in healthy humans as was previously shown in 
schizophrenia patients (14). Carriers of the C102/G-1438-alleles exhibited a significantly lower PPI 
than subjects homozygous for the T102/A-1438-alleles. Interestingly, the PPI variance explained by 
these 5-HT2AR SNPs was comparable between both studies (schizophrenia patients: 11%; healthy 
controls: 10%), although we used different PPI paradigms and recruited the subjects in different 
European countries. Secondly, we were able to replicate the finding that male COMT Val158Met Met-
homozygotes display elevated PPI levels (12), but we were unable to detect this effect in our total 
mixed-sex sample. Roussos et al. (12) reported their COMT effects on PPI from a sample of male 
students and we initially confirmed this effect for schizophrenia patients in a sample consisting of 
nearly 70% males (13). The fact that one study did not find an impact of that polymorphism on PPI in 
female subjects (27) further supports the notion that the COMT Val158Met genotype might affect PPI 
only in male subjects. Furthermore, the COMT Met158-allele has also been reported to have a greater 
impact on cognitive function in males than females, and this sex-specific effect results most likely via 
transcriptional regulation by estrogens (28). The explained PPI variance by COMT genotype for the 
males in the present study was 13%, which is situated between the effect in Roussos male sample 
(25%) and our mixed-gender schizophrenia sample (9%). Thirdly, we could not replicate the finding 
of Hong et al. (11) who reported a moderate impact of the NRG-1 Arg38Gln polymorphism on PPI 
previously (7.9% variance explanation by NRG-1 genotype). In contrast to the lowered PPI levels in 
the homozygous A-allele carriers in Hong’s sample, we rather found slightly elevated PPI levels in 
this group. Thus, it is unlikely that our study was simply underpowered to generate the same effect. 
The mixed sample of Hong et al. (11) was indeed larger than ours but was heterogeneous, consisting 
of Caucasian and African Americans, schizophrenia patients and healthy controls, whereas our sample 
includes exclusively Caucasian healthy controls. Finally, Hong et al. assessed PPI only at an SOA of 
120 ms and they used a slightly weaker prepulse intensity (80 vs. 85 dB). However, a selective 
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analysis of our 120 msec SOA-condition still revealed a different PPI pattern (AA>GG>AG), which 
could also not explained by the slightly different prepulse intensity. Thus, the discrepant results may 
be most likely caused by different sample compositions. 
 
Importantly, the present finding on the 5-HT2AR polymorphsisms match nearly all criteria for a 
replication of a genotype-phenotype association proposed by the National Cancer Institute–National 
Human Genome Research Institute (NCI-NHGRI) Working Group on Replication in Association 
Studies (19): I.) We used a larger size than reported in the initial report, II.) We generated an 
independent data set, III.) We assessed the same phenotype, IV.). We found similar effect sizes in the 
same SNPs, V.) We used the same statistical tests, VI.) We had a rationale for reassessing these SNPs 
(susceptibility genes of schizophrenia), and VII.) We provide at least the same level of detail for study 
design, analysis, and sample characteristics as reported in the initial study. Moreover, all analysed 
genotype frequencies were distributed in accordance to the HWE so that genetic inhomogeneity of the 
investigated population is unlikely. 
 
The current meta-analyses of the SchizophreniaGene online database reveal that, among the four 
genetic variants investigated in the present study, only the 5-HT2AR A-1438G polymorphism is likely 
associated with the risk for schizophrenia (5-HT2AR A-1438G: Odds ratio in Caucasians (OR)=1.17; 
COMT Val158Met: OR=1.01; NRG-1 Arg38Gln: OR=0.97; www.schizophreniaforum.org)(18). 
Lower PPI in carriers of the 5-HT2AR A-1438G-G variant would therefore be consistent with the 
significant association of this allele with schizophrenia and the well-known PPI deficits in 
schizophrenia. The 5-HT2AR T102C and the A-1438G polymorphism are silent mutations but both 
may alter promoter activity and expression of 5-HT2ARs (29,30). Thus, the C-allele of the T102C 
variation and/or the G-allele of the A-1438G variation may cause lower 5-HT2AR densities in several 
brain areas that are involved in the processing of sensorimotor gating (14,31). Additionally, PPI 
deficits have also been reported in obsessive-compulsive disorder (32,33) and autism (34,35), in which 
both the 5-HT2AR A-1438G polymorphism have been implicated (36,37). On the other hand, the 
increased PPI in male COMT Val158Met Met-homozygotes could not be plausibly explained by the 
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assumed increase of dopamine in the prefrontal cortex, as initially suggested (12,13), because an 
activation of prefrontal dopamine receptors by a local infusion of apomorphine disrupted PPI in rats 
(38,39). Thus, the neurobiological basis of the COMT-genotype effect on PPI remains to be clarified.  
 
In conclusion, the present findings support the view that sensorimotor gating is strongly modulated by 
5-HT2AR A-1438G/T102C genotype independent of gender, whereas the COMT Val158Met genotype 
only influences PPI in male subjects. In concert with previous human and animal findings showing 
that PPI is affected by multiple mutations, it is suggested that PPI (like schizophrenia) is modulated by 
polygenetic factors. Future studies with larger samples are needed to explore the multiple single and 
epistatic effects of different gene mutations on PPI, which may provide also windows into the 
polygenetic causation of schizophrenia. 
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Table 1 Demographic data and psychophysiological parameters of healthy human volunteers grouped according to their 5-HT2A A-1438G and T102C receptor 
genotype (means and standard error of means in parentheses, adjusted for gender and smoking; gender and smoking in frequency data). 5-HT2A A-
1438G and T102C receptor polymorphisms were in complete linkage disequilibrium. 
5-HT2A A-1438G genotype (rs6311) AA AG GG      
5-HT2A T102C genotype (rs6313) TT TC CC Total F/Chi2 df/dferr p η2 
N 19 (19.6%) 42 (43.3%) 36 (37.1%) 97 (100%)     
Age 26.8 (1.7) 25.8 (0.9) 26.1 (0.9) 26.1 (0.6) 0.20 2/96 .82 .00 
Years of education 16.8 (0.9) 16.7 (0.4) 17.8 (0.6) 17.1 (0.3) 1.35 2/96 .26 .03 
Men in % 36.8 57.1 44.4 48.5 2.53 2 .28 - 
Smoker in % 36.8 21.4 27.8 26.8 1.61 2 .45 - 
First block, amplitude of pulse-alone trialsa 
(Arbitrary units) 
742 (95.3) 712 (64.1) 701 (68.5) 714 (41.0) 0.06 2/92 .94 .00 
Mean amplitude of pulse-alone trialsa 
(Arbitrary units) 
561 (84.3) 578 (56.7) 590 (60.6) 580 (36.4) 0.04 2/92 .96 .00 
Mean percent prepulse inhibitiona 
(mean across three SOA-conditions) 
41.3 (3.3) 28.3 (2.2) 31.2 (2.4) 31.9 (1.6) 5.28 2/92 .007b .10 
Percent early habituation of pulse-alone trialsa 
(between first and second block) 
19.2 (6.3) 23.6 (4.2) 16.9 (4.5) 20.2 (2.7) 0.61 2/92 .55 .01 
Percent total habituation of pulse-alone trialsa 
(between first and last block) 
34.2 (7.6) 28.9 (5.1) 26.0 (5.5) 28.9 (3.3) 0.38 2/92 .98 .01 
Habituation of pulse-alone trials across 4 blocksa 
(linear gradient coefficient b) 
-90.8 (19.4) -65.0 (13.0) -60.5 (14.0) -68.4 (8.4) 0.86 2/92 .43 .02 
aANCOVA, means adjusted by covariates gender and smoking. 
bSignificant p values 
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Table 2 Demographic data and psychophysiological parameters of healthy human volunteers grouped according to their Catechol O-methyltransferase (COMT) 
Val158Met genotype (means and standard error of means in parentheses, adjusted for gender and smoking; gender and smoking in frequency data).  
COMT Val158Met genotype (rs4680) MetMet ValMet ValVal Total F/Chi2 df/dferr p η2 
N 22 (23.7%) 53 (57.0%) 18 (19.4%) 93 (100%)     
Age 25.9 (1.3) 26.4 (0.9) 25.7 (0.9) 26.2 (0.6) 0.13 2/92 .88 .00 
Years of education 16.3 (0.7) 17.1 (0.4) 17.5 (0.8) 17.0 (0.3) 0.79 2/92 .46 .02 
Men in % 54.5 45.3 50.0 48.4 0.56 2 .76 - 
Smoker in % 27.3 28.3 16.7 25.8 0.98 2 .61 - 
First block, amplitude of pulse-alone trialsa 
(Arbitrary units) 
775 (88.1) 685 (56.8) 749 (68.5) 718 (42.1) 0.42 2/88 .66 .01 
Mean amplitude of pulse-alone trialsa 
(Arbitrary units) 
644 (76.6) 561 (49.4) 559(60.6) 580 (36.7) 0.45 2/88 .64 .01 
Mean percent prepulse inhibitiona 
(mean across three SOA-conditions) 
35.8 (3.2) 30.2 (2.1) 34.3 (3.5) 32.3 (1.7) 1.28 2/88 .28 .03 
Percent early habituation of pulse-alone trialsa 
(between first and second block) 
14.7 (5.8) 21.5 (3.8) 26.0 (4.5) 20.6 (2.8) 0.89 2/88 .41 .02 
Percent total habituation of pulse-alone trialsa 
(between first and last block) 
28.7 (7.0) 26.0 (4.5) 35.8 (7.7) 28.6 (3.3) 0.60 2/88 .55 .01 
Habituation of pulse-alone trials across 4 blocksa 
(linear gradient coefficient b) 
-74.2 (17.8) -57.1 (11.5) -97.9 (19.7) -69.1 (8.6) 1.65 2/88 .20 .04 
aANCOVA, means adjusted by covariates gender and smoking. 
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Table 3 Demographic data and psychophysiological parameters of healthy human volunteers grouped according to their neuregulin-1 (NRG-1) Arg38Gln 
genotype (means and standard error of means in parentheses, adjusted for gender and smoking; gender and smoking in frequency data).  
NRG-1 Arg38Gln genotype (rs3924999) AA AG GG Total F/Chi2 df/dferr p η2 
N 13 (13.1%) 47 (47.5%) 39 (39.4%) 99 (100%)     
Age 26.9 (1.9) 25.9 (0.9) 26.1 (0.8) 26.1 (0.6) 0.15 2/98 .86 .00 
Years of education 17.2 (0.6) 16.8 (0.4) 17.4 (0.6) 17.1 (0.3) 0.41 2/98 .66 .01 
Men in % 30.8 42.6 61.5 48.5 4.96 2 .08 - 
Smoker in % 7.7 29.8 28.2 26.3 2.69 2 .26 - 
First block, amplitude of pulse-alone trialsa 
(Arbitrary units) 
848 (114.7) 684 (59.6) 702 (66.0) 713 (40.6) 0.82 2/94 .45 .02 
Mean amplitude of pulse-alone trialsa 
(Arbitrary units) 
650 (101.7) 573 (52.8) 554(58.5) 576 (36.0) 0.33 2/94 .72 .01 
Mean percent prepulse inhibitiona 
(mean across three SOA-conditions) 
35.6 (4.3) 30.7 (2.2) 32.2 (2.4) 32.0 (1.6) 0.52 2/94 .60 .01 
Percent early habituation of pulse-alone trialsa 
(between first and second block) 
25.6 (7.5) 14.0 (3.9) 27.9 (4.3) 21.0 (2.7) 3.08 2/94 .05 .06 
Percent total habituation of pulse-alone trialsa 
(between first and last block) 
46.3 (9.0) 23.6 (4.7) 31.0 (5.2) 29.5 (3.2) 2.59 2/94 .08 .05 
Habituation of pulse-alone trials across 4 blocksa 
(linear gradient coefficient b) 
-113.5 (23.1) -57.6 (12.0) -67.8 (13.3) -69.0 (8.3) 2.31 2/94 .11 .05 
aANCOVA, means adjusted by covariates gender and smoking. 
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Figure legends 
 
Figure 1: The effects of genotype on percent prepulse inhibition (PPI) of the acoustic startle 
response at prepulse (onset)-to-pulse (onset) intervals of 30, 60, and 120 ms in healthy 
human volunteers (means and standard errors of means, adjusted for gender and 
smoking): a) the completely linked 5-HT2A A-1438G and T102C receptor 
polymorphisms (Tukey-HSD post hoc test vs. TT/AA-allele group: *p<.05, **p<.01), 
b) the Catechol O-methyltransferase (COMT) Val158Met polymorphism, and c) the 
neuregulin-1 (NRG-1) Arg38Gln polymorphism. 
 
Figure 2: The effects of Catechol O-methyltransferase (COMT) Val158Met genotype on 
percent prepulse inhibition (PPI) of the acoustic startle response at prepulse (onset)-
to-pulse (onset) intervals of 30, 60, and 120 ms in 45 healthy human male volunteers 
(means and standard errors of means, adjusted for smoking; Tukey-HSD post hoc test 
vs. the MetMet-group: (*)p=.08, *p<.05). 
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